As of Mar 23
| -0.07 / -0.50%|
The 6 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 19.50, with a high estimate of 22.00 and a low estimate of 17.00. The median estimate represents a +38.69% increase from the last price of 14.06.
The current consensus among 6 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.